Synta's lung cancer drug ganetespib wins fast-track status from FDA

09/16/2013 | Pharmaceutical Business Review Online

The FDA granted fast-track designation to Synta Pharmaceuticals' ganetespib, which is being developed as a therapy for metastatic nonsmall-cell lung adenocarcinoma. The drug, a heat shock protein 90 inhibitor, is in a midstage and late-stage trial program.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC